The TGA has approved donanemab for Alzheimer’s disease. How does this drug work and who will be able to access it?
(Version anglaise seulement)
par Steve Macfarlane, Head of Clinical Services, Dementia Support Australia, & Associate Professor of Psychiatry, Monash University
Donanemab is only for use in the early stages of Alzheimer’s disease. And for now at least, it comes with a hefty price tag.
Lire l'article complet
© La Conversation
-
vendredi 23 mai 2025
